Journal
ANNALS OF INTERNAL MEDICINE
Volume 138, Issue 10, Pages 807-811Publisher
AMER COLL PHYSICIANS
DOI: 10.7326/0003-4819-138-10-200305200-00008
Keywords
-
Categories
Ask authors/readers for more resources
Background: Etanercept and infliximab are U.S. Food and Drug Administration-approved tumor necrosis factor (TNF) antagonists. Objective: To describe adverse event reports of heart failure after TNF antagonist therapy. Design: Case series. Setting: The U.S. Food and Drug Administration's MedWatch program. Patients: 47 patients who developed new or worsening heart failure during TNF antagonist therapy. Measurements: Clinical and laboratory reports. Results: After TNF antagonist therapy, 38 patients developed new-onset heart failure and 9 patients experienced heart failure exacerbation. Of the 38 patients with new-onset heart failure, 19 (50%) had no identifiable risk factors. Ten patients younger than 50 years of age developed new-onset heart failure after receiving TNF antagonists. After TNF antagonist therapy was discontinued and heart failure therapy was started in these 10 patients, 3 had complete resolution of heart failure, 6 improved, and 1 died. Conclusion: in a fraction of patients, TNF antagonists might induce new-onset heart failure or exacerbate existing disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available